Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?

Antiviral Research

Volumn 105, Issue 1, 2014, Pages 64-71

  Schneider, Maximilian David ^a   Sarrazin, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Direct acting antivirals; Drug resistance; Hepatitis C virus; Sequencing

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; FALDAPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN; VIRUS RNA; NUCLEOTIDE;

ANTIVIRAL THERAPY; DRUG TREATMENT FAILURE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MICROBIAL SENSITIVITY TEST; MISSENSE MUTATION; VIROLOGY; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RETREATMENT; SEQUENCE ANALYSIS; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT FAILURE; WILD TYPE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896520682     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.02.011     Document Type: Note

References (76)

1. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, F. Poordad, Z.D. Goodman, H.L. Sings, N. Boparai, M. Burroughs, C.A. Brass, J.K. Albrecht, and R. Esteban HCV RESPOND-2 Investigators, Boceprevir for previously treated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1207 1217
2. R.J.O. Barnard, J.A. Howe, R.A. Ogert, S. Zeuzem, F. Poordad, S.C. Gordon, R. Ralston, X. Tong, V. Sniukiene, J. Strizki, D. Ryan, J.M. Long, P. Qiu, C.A. Brass, J. Albrecht, M. Burroughs, S. Vuocolo, and D.J. Hazuda Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies Virology 444 2013 329 336
3. D.J. Bartels, J.C. Sullivan, E.Z. Zhang, A.M. Tigges, J.L. Dorrian, S. De Meyer, D. Takemoto, E. Dondero, A.D. Kwong, G. Picchio, and T.L. Kieffer Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment J. Virol. 87 2013 1544 1553
4. K. Berger, R. Bethell, M. Cartier, M. Marquis, I. Triki, W.O. Boecher, Y. Datsenko, G.G. Steinmann, J. Scherer, J.O. Stern, and G. Kukolj Analysis of baseline polymorphisms and persistence of emergent variants from phase Ib and II trials evaluating the HCV NS3 protease inhibitor BI 201335 Hepatology 56 2012 574A-574A
5. K.L. Berger, L. Lagace, I. Triki, M. Cartier, M. Marquis, C. Lawetz, R. Bethell, J. Scherer, and G. Kukolj Viral resistance in hepatitis C Virus genotype 1-infected patients receiving the NS3 protease inhibitor faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study Antimicrob. Agents Chemother. 57 2013 4928 4936
6. C. Brass, R.J.O. Barnard, J.A. Howe, R.A. Ogert, R. Ralston, N. Boparai, M. Burroughs, V. Sniukiene, P. Mendez, and J. Albrecht Sustained virologic response and Boceprevir resistance-associated variants observed in patients infected with HCV Genotpype 1a/1b when treated with Boceprevir plus Peginterferon alfa-2b/Ribavirin J. Hepatol. 54 2011 S471 S472
7. S. De Meyer, I. Dierynck, A. Ghys, M. Beumont, B. Daems, B. Van Baelen, J.C. Sullivan, D.J. Bartels, T.L. Kieffer, S. Zeuzem, and G. Picchio Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial Hepatology 56 2012 2106 2115
8. S. De Meyer, A. Ghys, G.R. Foster, M. Beumont, B. Van Baelen, T.I. Lin, I. Dierynck, H. Ceulemans, and G. Picchio Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes J. Viral Hepatitis 20 2013 395 403
9. G.J. Dore, E. Lawitz, C. Hezode, S. Shafran, A. Ramji, H. Tatum, G. Taliani, A. Tran, M. Brunetto, S. Zaltron, S. Strasser, N. Weis, W. Ghesquiere, S. Lee, D. Larrey, S. Pol, H. Harley, J. George, S. Fung, V. De Ledinghen, P. Hagens, D. Cohen, E. Cooney, S. Noviello, and E. Hughes Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT2/3 study J. Gastroenterol. Hepatol. 28 2013 155 156
10. P. Ferenci, T. Asselah, G.R. Foster, S. Zeuzem, C. Sarrazin, C. Moreno, D. Ouzan, M. Maevskaya, F. Calinas, L.E. Morano, J. Crespo, J.F. Dufour, M. Bourliere, K. Agarwal, D. Forton, M. Schuchmann, E. Zehnter, S. Nishiguchi, M. Omata, J. Stern, Y. Datzenko, J. Scherer, and A.M. Quinson Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial J. Gastroenterol. Hepatol. 28 2013 157 158
11. X. Forns, E. Lawitz, S. Zeuzem, E. Gane, J.-P. Bronowicki, P. Andreone, A. Horban, A. Brown, M. Peeters, O. Lenz, S. Ouwerkerk-Mahadevan, J. Scott, R. Kalmeijer, G. De La Rosa, R. Sinha, and M. Beumont-Mauviel Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial Hepatology 58 2013 737A 738A
12. G.R. Foster, C. Hezode, J.P. Bronowicki, G. Carosi, O. Weiland, L. Verlinden, R. van Heeswijk, B. van Baelen, G. Picchio, and M. Beumont Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections Gastroenterology 141 2011 U604 U881
13. R.A. Fridell, D.K. Qiu, C.F. Wang, L. Valera, and M. Gao Resistance analysis of the hepatitis C virus NS5A Inhibitor BMS-790052 in an in vitro Replicon system Antimicrob. Agents Chemother. 54 2010 3641 3650
14. E.J. Gane, P. Pockros, S. Zeuzem, P. Marcellin, A. Shikhman, C. Bernaards, E.S. Yetzer, N. Shulman, X. Tong, I. Najera, A. Bertasso, J. Hammond, and S. Stancic Interferon-free treatment with a combination of mericitabine and danoprevir/R with or without ribavirin in treatment-naive HCV genotype 1-infected patients J. Hepatol. 56 2012 S555 S556
15. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, R.A. Fridell, M.H. Serrano-Wu, D.R. Langley, J.H. Sun, D.R. O'Boyle 2nd, J.A. Lemm, C. Wang, J.O. Knipe, C. Chien, R.J. Colonno, D.M. Grasela, N.A. Meanwell, and L.G. Hamann Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
16. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
17. P. Halfon, and C. Sarrazin Future treatment of chronic hepatitis C with direct acting antivirals: Is resistance important? Liver Int. 32 Suppl. 1 2012 79 87
18. A. Howe, J. Long, S. Thompson, R. Barnard, K. Alves, J. Howe, and J. Wahl Interim analysis of the durability of response and persistence of resistance associated variants during long term follow after boceprevir + pegylated interferon/ribavirin Hepatology 2013 58
19. J. Howe, J. Long, S. Black, R. Chase, P. McMonagle, S. Curry, Z. Guo, and A. Howe Pooled clinical trial analyses of the effects of detectable baseline HCV NS3/4a resistance-associated variants on the efficacy of boceprevir + pegylated interferon/ribavirin therapy Hepatology 2013 58
20. I. Jacobson, T. Asselah, P. Ferenci, G. Foster, D. Jensen, F. Negro, P. Mantry, D. Wright, X. Forns, J. Garcia-Samaniego, C. Oliveira, A. Carvalho, D. Forton, K. Agarwal, K. Arastéh, C. Cooper, W. Ghesquiere, J.-F. Dufour, Y. Sakai, Y. Tanaka, J. Stern, N. Sha, W. Boecher, G. Steinmann, and A. Quinson STARTVerso3: A randomized, double-blind, placebo- controlled phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treat- ment-experienced patients with chronic hepatitis C genotype-1 infection Hepatology 58 2013 742A
21. I. Jacobson, G.J. Dore, G.R. Foster, M.W. Fried, M. Radu, V.V. Rafalskiy, L. Moroz, A. Craxi, M. Peeters, O. Lenz, S. Ouwerkerk-Mahadevan, R. Kalmeijer, and M. Beumont-Mauviel Simeprevir (TMC435) with Peginterferon/Ribavirin for chronic HCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial J. Hepatol. 58 2013 S574-S574
22. I. Jacobson, R. Ghalib, M. Rodriguez-Torres, Z. Younossi, A. Corregidor, M. Sulkowski, E. DeJesus, B. Pearlman, M. Rabinovitz, N. Gitlin, J. Lim, P. Pockros, B. Fevery, T. Lambrecht, S. Ouwerkerk-Mahadevan, K. Callewaert, W. Symonds, G. Picchio, K. Lindsay, M. Beumont-Mauviel, and E. Lawitz SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study Hepatology 58 2013 58
23. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, M.S. Sulkowski, M.L. Shiffman, E. Lawitz, G. Everson, M. Bennett, E. Schiff, M.T. Al-Assi, G.M. Subramanian, D. An, M. Lin, J. McNally, D. Brainard, W.T. Symonds, J.G. McHutchison, K. Patel, J. Feld, S. Pianko, and D.R. Nelson Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N. Engl. J. Med. 368 2013 1867 1877
24. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, R. Flisiak, J. George, M. Rizzetto, D. Shouval, R. Sola, R.A. Terg, E.M. Yoshida, N. Adda, L. Bengtsson, A.J. Sankoh, T.L. Kieffer, S. George, R.S. Kauffman, S. Zeuzem, and A.S. Team Telaprevir for previously untreated chronic hepatitis C virus infection N. Engl. J. Med. 364 2011 2405 2416
25. Y. Karino, J. Toyota, K. Ikeda, F. Suzuki, K. Chayama, Y. Kawakami, H. Ishikawa, H. Watanabe, D. Hernandez, F. Yu, F. McPhee, and H. Kumada Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir J. Hepatol. 58 2013 646 654
26. C. Kuiken, P. Hraber, J. Thurmond, and K. Yusim The hepatitis C sequence database in Los Alamos Nucl. Acids Res. 36 2008 D512 D516
27. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, S.K. Young, B. Lee, D. Heckerman, J. Carlson, L.L. Reyor, M. Kleyman, C.M. McMahon, C. Birch, J. Schulze Zur Wiesch, T. Ledlie, M. Koehrsen, C. Kodira, A.D. Roberts, G.M. Lauer, H.R. Rosen, F. Bihl, A. Cerny, U. Spengler, Z. Liu, A.Y. Kim, Y. Xing, A. Schneidewind, M.A. Madey, J.F. Fleckenstein, V.M. Park, J.E. Galagan, C. Nusbaum, B.D. Walker, G.V. Lake-Bakaar, E.S. Daar, I.M. Jacobson, E.D. Gomperts, B.R. Edlin, S.M. Donfield, R.T. Chung, A.H. Talal, T. Marion, B.W. Birren, M.R. Henn, and T.M. Allen Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
28. L. Lagace, P.W. White, C. Bousquet, N. Dansereau, F. Do, M. Llinas-Brunet, M. Marquis, M.J. Massariol, R. Maurice, C. Spickler, D. Thibeault, I. Triki, S. Zhao, and G. Kukolj In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335 Antimicrob. Agents Chemother. 56 2012 569 572
29. A.M. Lam, E. Murakami, C. Espiritu, H.M.M. Steuer, C.R. Niu, M. Keilman, H.Y. Bao, V. Zennou, N. Bourne, J.G. Julander, J.D. Morrey, D.F. Smee, D.N. Frick, J.A. Heck, P.Y. Wang, D. Nagarathnam, B.S. Ross, M.J. Sofia, M.J. Otto, and P.A. Furman PSI-7851, a pronucleotide of beta-D-2 '-Deoxy-2 '-Fluoro-2 '-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication Antimicrob. Agents Chemother. 54 2010 3187 3196
30. Lawitz, E.; Forns, X.; Zeuzem, S.; Gane, E.; Bronowicki, J.-P.; Andreone, P.; Horban, A.; Brown, A.; Peeters, M.; Lenz, O.; Ouwerkerk-Mahadevan, S.; Kalmeijer, R.; Beumont-Mauviel, M. 2013a. Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients WHO Relapsed After Previous Interferon-Based Therapy: Results From Promise, a phase III Trial, Late-Breaking Abstract Session, Digestive Disease Week, Orlando.
31. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, S.C. Gordon, M. Schultz, M.N. Davis, Z. Kayali, K.R. Reddy, I.M. Jacobson, K.V. Kowdley, L. Nyberg, G.M. Subramanian, R.H. Hyland, S. Arterburn, D. Jiang, J. McNally, D. Brainard, W.T. Symonds, J.G. McHutchison, A.M. Sheikh, Z. Younossi, and E.J. Gane Sofosbuvir for previously untreated chronic hepatitis C infection N. Engl. J. Med. 368 2013 1878 1887
32. E. Lawitz, F. Poordad, D. Brainard, R. Hyland, D. An, W. Symonds, J. McHutchison, and F. Membreno Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study Hepatology 58 2013
33. E. Lawitz, F. Poordad, R. Hyland, X. Ding, C. Hebner, P. Pang, W. Symonds, J. McHutchison, and F. Membreno Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin resulted in ≥95% sustained virologic response in patients with HCV genotype 1, including patients with cirrhosis: the LONESTAR trial Hepatology 58 2013 315A 316A
34. O. Lenz, J. de Bruijne, L. Vijgen, T. Verbinnen, C. Weegink, H. Van Marck, I. Vandenbroucke, M. Peeters, K. Simmen, G. Fanning, R. Verloes, G. Picchio, and H. Reesink Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy Gastroenterology 143 2012 1176-8.e1-6
35. O. Lenz, B. Fevery, T. Verbinnen, L. Tambuyzer, L. Vijgen, M. Peeters, M. Beumont-Mauviel, G. Picchio, and S. De Meyer Resistance analyses of HCV isolates from patients treated with simeprevir in phase IIB/III studies Hepatology 58 2013 743A
36. O. Lenz, T. Verbinnen, T.I. Lin, L. Vijgen, M.D. Cummings, J. Lindberg, J.M. Berke, P. Dehertogh, E. Fransen, A. Scholliers, K. Vermeiren, T. Ivens, P. Raboisson, M. Edlund, S. Storm, L. Vrang, H. de Kock, G.C. Fanning, and K.A. Simmen In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrob. Agents Chemother. 54 2010 1878 1887
37. O. Lenz, L. Vijgen, J.M. Berke, M.D. Cummings, B. Fevery, M. Peeters, G. De Smedt, C. Moreno, and G. Picchio Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202) J. Hepatol. 58 2013 445 451
38. C. Lin, K. Lin, Y.P. Luong, B.G. Rao, Y.Y. Wei, D.L. Brennan, J.R. Fulghum, H.M. Hsiao, S. Ma, J.P. Maxwell, K.M. Cottrell, R.B. Perni, C.A. Gates, and A.D. Kwong In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms J. Biol. Chem. 279 2004 17508 17514 (Pubitemid 38560514)
39. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, R. Ghalib, R. Reindollar, V. Rustgi, F. McPhee, M. Wind-Rotolo, A. Persson, K. Zhu, D.I. Dimitrova, T. Eley, T. Guo, D.M. Grasela, and C. Pasquinelli Preliminary study of two antiviral agents for hepatitis C genotype 1 N. Engl. J. Med. 366 2012 216 224
40. M. Manns, P. Marcellin, F.P.F. Poordad, E.S.A. de Araujo, M. Buti, Y. Horsmans, E.J.E. Janczewska, F. Villamil, M. Peeters, O. Lenz, S. Ouwerkerk-Mahadevan, R. Kalmeijer, and M. Beumont-Mauviel Simeprevir (TMC435) with peginterferon-α2a or -α2b and ribavirin in treatment-naïve HCV genotype 1 patients: QUEST-2, a randomised phase III trial J. Hepatol. 58 2013 S568-S568
41. M.F. McCown, S. Rajyaguru, S. Kular, N. Cammack, and I. Nájera GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796 Antimicrob. Agents Chemother. 53 2009 2129 2132
42. F. McPhee, J. Toyota, K. Chayama, H. Miyagoshi, E. Tamura, H. Ishikawa, E. Hughes, D. Hernandez, and H. Kumada Analysis of HCV resistance variants in a phase 3 trial of daclatasvir combined with asunaprevir for Japanese patients with genotype 1b infection Hepatology 58 2013 749A
43. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, and A.S. Perelson Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107 (Pubitemid 28471138)
44. S. Paolucci, L. Fiorina, A. Piralla, R. Gulminetti, S. Novati, G. Barbarini, P. Sacchi, M. Gatti, L. Dossena, and F. Baldanti Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients Virol. J. 9 2012 245
45. S. Pol, J. Aerssens, S. Zeuzem, P. Andreone, E.J. Lawitz, S. Roberts, Z. Younossi, G.R. Foster, R. Focaccia, A. Horban, P.J. Pockros, R.P. Van Heeswijk, S. De Meyer, D. Luo, M. Botfield, M. Beumont, and G. Picchio Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure J. Hepatol. 58 2013 883 889
46. F. Poordad, J.P. Bronowicki, S.C. Gordon, S. Zeuzem, I.M. Jacobson, M.S. Sulkowski, T. Poynard, T.R. Morgan, C. Molony, L.D. Pedicone, H.L. Sings, M.H. Burroughs, V. Sniukiene, N. Boparai, V.S. Goteti, C.A. Brass, J.K. Albrecht, and B.R. Bacon Factors that predict response of patients with hepatitis C virus infection to boceprevir Gastroenterology 2012 2012 AGA Institute, Elsevier Inc.
47. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, S. Siggelkow, M. Heckaman, L. Larsen, R. Menon, G. Koev, R. Tripathi, T. Pilot-Matias, and B. Bernstein Exploratory study of oral combination antiviral therapy for hepatitis C N. Engl. J. Med. 368 2013 45 53
48. F. Poordad, M.P. Manns, P. Marcellin, E.S.A. de Araujo, M. Buti, Y. Horsmans, E. Janczewska, F. Villamil, M. Peeters, O. Lenz, S. Ouwerkerk-Mahadevan, R. Kalmeijer, and M. Beumont-Mauviel Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial Gastroenterology 144 2013 S151-S151
49. F. Poordad, J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, I.M. Jacobson, K.R. Reddy, Z.D. Goodman, N. Boparai, M.J. DiNubile, V. Sniukiene, C.A. Brass, J.K. Albrecht, and J.P. Bronowicki SPRINT-2 Investigators, Boceprevir for untreated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1195 1206
50. S. Rajyaguru, S. Xu, C. Hebner, E. Svarovskaia, V. Gontcharova, B. Doehle, M. Miller, and H. Mo Sofosbuvir selects the NS5B S282T mutation in vitro in genotype 1-6 replicons and is not cross-resistant to resistance associated variants selected by other classes of antiviral inhibitors Hepatology 58 2013 739A
51. H.W. Reesink, G.C. Fanning, K. Abou Farha, C. Weegink, A. Van Vliet, G. van 't Klooster, O. Lenz, F. Aharchi, K. Marien, P. Van Remoortere, H. de Kock, F. Broeckaert, P. Meyvisch, E. Van Beirendonck, K. Simmen, and R. Verloes Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients Gastroenterology 138 2010 913 921
52. K.P. Romano, A. Ali, C. Aydin, D. Soumana, A. Ozen, L.M. Deveau, C. Silver, H. Cao, A. Newton, C.J. Petropoulos, W. Huang, and C.A. Schiffer The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors PLoS Pathog. 8 2012 e1002832
53. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, Y. Zhou, H.M. Chu, C. Lin, C. Weegink, H. Reesink, S. Zeuzem, and A.D. Kwong Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777 (Pubitemid 46677938)
54. C. Sarrazin, H.W. Reesink, S. Zeuzem, I. Dierynck, D. Luo, J. Witek, G. Picchio, and S. De Meyer Treatment with telaprevir/Peg-IFN/RBV after 14-day telaprevir exposure in phase I studies: results from the phase IIIB C219 rollover study J. Hepatol. 58 2013 S369 S370
55. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
56. K.E. Sherman, M.S. Sulkowski, F. Zoulim, A. Alberti, L.J. Wei, J. Sullivan, E.C. Martin, T.L. Kieffer, S. De Meyer, G. Picchio, C.S. Graham, and S. Zeuzem Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis of the extend study Hepatology 54 2011 485A 486A
57. M.O. Silva, M. Treitel, D.J. Graham, S. Curry, M.J. Frontera, P. McMonagle, S. Gupta, E. Hughes, R. Chase, F. Lahser, R.J.O. Barnard, A.Y.M. Howe, and J.A. Howe Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3 J. Hepatol. 59 2013 31 37
58. J.M. Strizki, R.J.O. Barnard, C. Cheney, C. McHale, D. Graham, A. Himmelberger, A. Petry, I. Fraser, R. Nachbar, and D.J. Hazuda Evaluation of NS3 amino acid variants in a phase 1b study of genotype 1 (GT1) and GT3 infected patients with the HCV protease inhibitor, MK-5172 J. Hepatol. 56 2012 S479-S479
59. M.S. Sulkowski, T. Asselah, J. Lalezari, P. Ferenci, H. Fainboim, B. Leggett, F. Bessone, S. Mauss, J. Heo, Y. Datsenko, J.O. Stern, G. Kukolj, J. Scherer, G. Nehmiz, G.G. Steinmann, and W.O. Bocher Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial Hepatology 57 2013 2143 2154
60. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, I. Jacobson, E. Lawitz, A.S. Lok, F. Hinestrosa, P.J. Thuluvath, H. Schwartz, D.R. Nelson, G.T. Everson, T. Eley, M. Wind-Rotolo, S.P. Huang, M. Gao, D. Hernandez, F. McPhee, D. Sherman, R. Hindes, W. Symonds, C. Pasquinelli, and D.M. Grasela Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N. Engl. J. Med. 370 2014 211 221
61. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, I. Jacobson, E. Lawitz, A.S. Lok, F. Hinestrosa, P.J. Thuluvath, H. Schwartz, D.R. Nelson, G.T. Everson, T. Eley, M. Wind-Rotolo, S.P. Huang, M. Gao, F. McPhee, D. Hernandez, D. Sherman, R. Hindes, W. Symonds, C. Pasquinelli, D.M. Grasela, and A.I.S. Grp Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC) J. Hepatol. 58 2013 S570-S570
62. J.C. Sullivan, S. De Meyer, D.J. Bartels, I. Dierynck, E.Z. Zhang, J. Spanks, A.M. Tigges, A. Ghys, J. Dorrian, N. Adda, E.C. Martin, M. Beumont, I.M. Jacobson, K.E. Sherman, S. Zeuzem, G. Picchio, and T.L. Kieffer Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials Clin. Infect Dis. 57 2013 221 229
63. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, U. Karey, E. Hughes, R. Ralston, X. Tong, E. Herrmann, S. Zeuzem, and C. Sarrazin Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
64. E. Svarovskaia, H. Dvory, C. Hebner, B. Doehle, V. Gontcharova, R. Martin, E. Gane, I. Jacobson, D. Nelson, E. Lawitz, B. Bekele, D. Brainard, W. Symonds, J. McHutchison, M. Miller, and H. Mo No resistance detected in four phase 3 clinical studies in HCV genotype 1-6 of sofosbuvir + ribavirin with or without peginterferon Hepatology 58 2013 1091A
65. E. Svarovskaia, H. Dvory-Sobol, V. Gontcharova, R. Martin, R. Hyland, W.T. Symonds, J. Lalezari, M.D. Miller, and H. Mo No S282T mutation detected by deep sequencing in a large number of HCV patients who received sofosbuvir with RBV and/or GS-0938: the quantum study J. Hepatol. 58 2013 S496-S496
66. E.S. Svarovskaia, H. Dvory-Sobol, V. Gontcharova, S. Chiu, C. Hebner, R.H. Hyland, K.V. Kowdley, E. Lawitz, E.J. Gane, W.T. Symonds, J.G. McHutchison, M.D. Miller, and H.M. Mo Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7977)-containing regimens in phase 2 studies Hepatology 56 2012 551A-551A
67. X. Tong, R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, and B.A. Malcolm Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Antiviral Res. 70 2006 28 38
68. T. Verbinnen, H. Van Marck, I. Vandenbroucke, L. Vijgen, M. Claes, T.I. Lin, K. Simmen, J. Neyts, G. Fanning, and O. Lenz Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing J. Virol. 84 2010 11124 11133
69. J. Vermehren, and C. Sarrazin The role of resistance in HCV treatment Best Pract. Res. Clin. Gastroenterol. 26 2012 487 503
70. J. Vermehren, S. Susser, C.M. Lange, N. Forestier, U. Karey, E. Hughes, R. Ralston, X. Tong, S. Zeuzem, and C. Sarrazin Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b J. Viral Hepat. 19 2012 120 127
71. J.M. Vierling, S. Zeuzem, F. Poordad, J.P. Bronowicki, M.P. Manns, B.R. Bacon, R. Esteban, S.L. Flamm, P.Y. Kwo, L.D. Pedicone, W. Deng, F.J. Dutko, M.J. DiNubile, K.J. Koury, F.A. Helmond, J. Wahl, and S. Bruno Safety and efficacy of boceprevir/PEG-Interferon/ribavirin (BOC/P/R) combination therapy for chronic HCV G1 patients with compensated cirrhosis: a meta-analyses of five phase 3 clinical trials J. Hepatol. 58 2013 S576 S577
72. C.F. Wang, J.H. Sun, D.R. O'Boyle, P. Nower, L. Valera, S. Roberts, R.A. Fridell, and M. Gao Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir Antimicrob. Agents Chemother. 57 2013 2054 2065
73. C. Welsch, and S. Zeuzem Clinical relevance of HCV antiviral drug resistance Curr. Opin. Virol. 2 2012 651 655
74. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, R. Focaccia, Z. Younossi, G.R. Foster, A. Horban, P. Ferenci, F. Nevens, B. Müllhaupt, P. Pockros, R. Terg, D. Shouval, B. van Hoek, O. Weiland, R. Van Heeswijk, S. De Meyer, D. Luo, G. Boogaerts, R. Polo, G. Picchio, M. Beumont, and R.S. Team Telaprevir for retreatment of HCV infection N. Engl. J. Med. 364 2011 2417 2428
75. S. Zeuzem, G. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, R. Hyland, A. Illeperuma, E. Svarovskaia, D. Brainard, W. Symonds, J. McHutchison, O. Weiland, H. Reesink, P. Ferenci, C. Hezode, and R. Esteban Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial Hepatology 58 2013 733A
76. S. Zeuzem, V. Soriano, T. Asselah, J.-P. Bronowicki, A.W. Lohse, B. Mullhaupt, M. Schuchmann, M. Bourliere, M. Buti, S.K. Roberts, E.J. Gane, J.O. Stern, R. Vinisko, G. Kukolj, J.-P. Gallivan, W.-O. Bocher, and F.J. Mensa Faldaprevir and deleobuvir for HCV genotype 1 infection N. Engl. J. Med. 369 2013 630 639